1315 Capital

1315 Capital is a U.S. private investment firm founded in 2014 and headquartered in Philadelphia, Pennsylvania, investing in pharmaceutical, medical-technology (medtech), and healthcare-services growth-stage companies. The firm was founded by Managing Partners Adele C. Oliva (previously at Apax Partners, Quaker BioVentures, and other leading healthcare-PE firms) and Michael Koby (previously at Safeguard Scientifics and Apax Partners). 1315 Capital operates as a dedicated healthcare-and-life-sciences growth-equity investor, positioning between traditional early-stage biotech VC and large-scale healthcare buyout PE. The firm has raised multiple institutional funds (1315 Capital I in 2014 at USD 155 million, 1315 Capital II in 2018 at USD 300 million, 1315 Capital III in 2022 at approximately USD 525 million) with aggregate AUM approaching or exceeding USD 1 billion across vintages, typically writing initial check sizes in the USD 10 to 40 million range at Series B / Series C and growth-equity stages. Notable portfolio companies have included Blood Centers of America, DermoSafe, various specialty-pharmaceutical and medtech companies producing multiple exits.